Alnylam Pharmaceuticals, Inc. (ALNY)

Basic

  • Market Cap

    $20.58B

  • EV

    $20.84B

  • Shares Out

    125.49M

  • Revenue

    $1,723.61M

  • Employees

    2,002

Margins

  • Gross

    84%

  • EBITDA

    -17.38%

  • Operating

    -20.56%

  • Pre-Tax

    -29.17%

  • Net

    -29.58%

  • FCF

    -3.86%

Returns (5Yr Avg)

  • ROA

    -20.43%

  • ROE

    -163.33%

  • ROCE

    -38.18%

  • ROIC

    -125.16%

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    $225.25

  • P/E

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

Per Share

  • Rev

    $13.86

  • Earnings (Dil)

    -$4.11

  • FCF

    -$0.54

  • Book Value

    -$1.32

Growth (CAGR)

  • Rev 3Yr

    62.6%

  • Rev 5Yr

    79.77%

  • Rev 10Yr

    44.05%

  • Dil EPS 3Yr

    -19.32%

  • Dil EPS 5Yr

    -10.02%

  • Dil EPS 10Yr

    7.33%

  • Rev Fwd 2Yr

    30.79%

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    29%

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Select a metric from the list below to chart it

Dec '13
Dec '15
Dec '17
Dec '19
Dec '21
LTM
Metric
Dec '13
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
LTM

Total Revenues

74.9

219.8

492.9

844.3

1,037.4

1,723.6

Total Revenues % Chg.

-16.7%

193.4%

124.3%

71.3%

22.9%

79.4%

Cost of Goods Sold, Total

1.8

25.1

78.1

140.1

168.8

275.8

Gross Profit

73.1

194.7

414.8

704.1

868.6

1,447.8

Selling General & Admin Expenses, Total

424.5

533.7

588.4

620.6

770.7

807.9

R&D Expenses

463.3

600.5

654.8

792.2

883.0

994.3

Other Operating Expenses, Total

887.8

1,134.1

1,243.2

1,412.8

1,653.7

1,802.2

Operating Income

-814.7

-939.4

-828.4

-708.7

-785.1

-354.4

Interest Expense, Total

—

—

-84.5

-143.0

-156.0

-119.8

Interest And Investment Income

29.3

33.4

11.8

1.6

24.8

79.2

Net Interest Expenses

29.3

33.4

-72.7

-141.4

-131.2

-40.6

Other Non Operating Income (Expenses)

21.2

9.4

-8.5

-57.7

-100.9

-97.0

EBT, Excl. Unusual Items

-764.2

-896.5

-909.6

-907.8

-1,017.1

-491.9

Gain (Loss) On Sale Of Investments

3.6

11.3

54.0

55.7

-33.3

-10.9

In Process R&D Expenses

—

—

—

—

—

—

Other Unusual Items

—

—

—

—

-76.6

—

EBT, Incl. Unusual Items

-760.7

-885.3

-855.6

-852.1

-1,127.0

-502.9

Income Tax Expense

0.8

0.9

2.7

0.7

4.2

7.0

Earnings From Continuing Operations

-761.5

-886.1

-858.3

-852.8

-1,131.2

-509.9

Net Income

-761.5

-886.1

-858.3

-852.8

-1,131.2

-509.9

Net Income to Common Incl Extra Items

-761.5

-886.1

-858.3

-852.8

-1,131.2

-509.9

Net Income to Common Excl. Extra Items

-761.5

-886.1

-858.3

-852.8

-1,131.2

-509.9

Total Shares Outstanding

101.2

112.2

116.4

120.2

123.9

125.5

Weighted Avg. Shares Outstanding

100.6

109.3

115.0

118.5

121.7

124.3

Weighted Avg. Shares Outstanding Dil

100.6

109.3

115.0

118.5

121.7

124.3

EPS

-7.6

-8.1

-7.5

-7.2

-9.3

-4.1

EPS Diluted

-7.6

-8.1

-7.5

-7.2

-9.3

-4.1

EBITDA

-799.4

-922.3

-793.7

-661.1

-740.6

-299.5